Entera Bio Appoints Dr. Juan Camilo Arjona Ferreira to Board of Directors
Entera Bio Ltd. has announced the appointment of Dr. Juan Camilo Arjona Ferreira to its Board of Directors, effective December 1, 2026.
Stocks · News reference
Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9
Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Entera Bio Ltd. (ENTX)
Filed: 2026-10-27 AccNo: 0001178913-26-004854 Size: 225 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia)These
Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rose, but Alignment Healthcare plunged 24% after a Medicare contract downgrade; telecom and other stocks also fell premarket.
Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.
Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Entera Bio (NASDAQ:ENTX) with a Overweight rating.